Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1972
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral (based On Typical Administration In Early-phase Antiretroviral Trials; Not Explicitly Stated In Sources)
01
Overview
MK-1972 is a small molecule drug that was developed by Merck Sharp & Dohme for the treatment of HIV infections. It was investigated primarily as an antiretroviral agent in immune system diseases, infectious diseases, and urogenital diseases, with its main clinical focus on HIV-1 infection. The drug reached Phase 1 clinical trials but development was ultimately discontinued. The specific mechanism of action and molecular target for MK-1972 have not been publicly disclosed[1][2][3].
Beyond the preview
Go deeper on MK-1972.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1972.